CE Dinner Meeting at the Sheraton Palo Alto: Early Stage T1D

Sheraton Palo Alto Hotel
625 El Camino Real
Palo Alto, CA 94301

Wednesday, October 29, 2025 at 5:00pm PT - Wednesday, October 29, 2025 at 10:00pm PT
Add this event to your calendar

625 El Camino Real, Palo Alto, CA 94301

Info

Topic

The DETECT T1D Live Summit series has been designed to bring together multidisciplinary faculty and a type 1 diabetes (T1D) patient advocate to discuss practical considerations in screening, follow-up, early referral, and treatment to delay T1D progression. The program focus will also address both clinician and patient challenges to optimize early identification and patient selection. This program will feature small group breakout discussions to analyze relevant cases and offer an opportunity to access a learning gallery featuring additional educational aids and resources to reinforce engagement and boost understanding of evolving concepts in early-stage T1D.

Credits Offered

This event offers 3.5 contact hours to attendees.
Accreditation Info: ANCC.

Additional Information

TARGET AUDIENCE

This activity is designed to meet the educational needs of multidisciplinary clinicians who refer, treat or see patients with or at high risk for T1D is needed, including primary care clinicians, pediatricians, pediatric & adult endocrinologists, diabetes educators, infusion professionals and other allied healthcare professionals.

LEARNING OBJECTIVES

Upon completion of this activity, attendees will have improved ability to:

  1. Identify criteria for T1D screening, focusing on high-risk patients to facilitate timely referral and monitoring
  2. Incorporate evidence-based strategies for presymptomatic T1D screening into routine clinical practice to improve early detection
  3. Develop workflows to appropriately monitor, follow-up, or refer individuals who are screened for T1D.
  4. Interpret T1D screening results and effectively communicate next steps to support patient education and inform treatment decisions.
  5. Develop strategies for establishing referral pathways and enhancing collaboration with specialists in order to enable earlier application of disease-modifying therapies for early stage T1D.
  6. Identify appropriate patients who would benefit from treatment with disease-modifying therapies for delaying T1D progression based on clinical evidence
  7. Implement protocols to support safe and efficient administration of disease-modifying therapies for T1D according to guidance and patient-specific factors.

PRELIMINARY AGENDA

5:00 PM – 6:00 PM • Learning Gallery and Networking Reception
During the networking reception, we will provide attendees with an opportunity to network with our speaking faculty, while enjoying an Immersive Learning Gallery Experience, that includes a number of engaging and interactive learning stations with the following components:

  • A virtual reality lounge, utilizing Oculus Headsets, with stunning VR 360 animations on optimal patient and physician interactions
  • Interactive Augmented Reality Headsets, where learners can manipulate their virtual environment to learn about T1D screening and diagnosis, in an exciting way
  • Create your own clinical practice poster and personalize it with your name and practice
    View our DETECT1D Website through touchscreens and get a tour of all of the free tools and resources for clinician and patient education
  • Manage life-sized interactive holographic AI patients Emma (pediatric/adolescent) and Mike (adult) where you can ask them questions and make real-time treatment decisions based on the patient’s responses

These engaging learning and networking opportunities with top thought leaders are offered before and after the live program to maximize your connections and knowledge to offer your patients the best chance to achieve optimal outcomes.

6:00 PM – 9:30 PM • Dinner/CME Presentation/Dessert

This interactive live presentation has been designed to bring together a multidisciplinary care team with a patient to discuss practical considerations in screening, follow-up, early referral, and treatment to prevent T1D progression, as well as how to best address clinician and patient challenges to optimize early identification and patient selection. In addition, this program features a moderator to reinforce engagement and encourage a deeper dive into recent advances. Program focus includes the latest consensus guidance for monitoring T1d, criteria, guidance, and practical considerations for teplizumab use, and a detailed discussion on emerging approaches for new onset (stage 3) T1D.

9:30 PM – 10:00PM • Learning Gallery 
Continuation of networking session, with an opportunity to engage with our expert faculty speakers and avail of the interactive learning stations described above.

Speakers

Ananta Addala
Ananta Addala DO, MPH

Assistant Professor of Pediatrics
Standford University
Stanford, California

Jay H. Shubrook
Jay H. Shubrook DO, FAAFP, FACOFP

Professor and Diabetologist
Department of Clinical Sciences and Community Health
Touro University California
Vallejo, CA

Interested in attending this event?

Enter your email address below to register for this event.
If you do not have an account, create your account.